Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned an average rating of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $8.63.

Separately, HC Wainwright restated a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Wednesday, February 26th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Mackenzie Financial Corp lifted its stake in Fulcrum Therapeutics by 412.5% in the fourth quarter. Mackenzie Financial Corp now owns 118,025 shares of the company’s stock valued at $555,000 after purchasing an additional 94,997 shares during the last quarter. Woodline Partners LP raised its stake in shares of Fulcrum Therapeutics by 110.3% in the fourth quarter. Woodline Partners LP now owns 1,410,520 shares of the company’s stock valued at $6,629,000 after buying an additional 739,713 shares during the period. Suvretta Capital Management LLC lifted its position in shares of Fulcrum Therapeutics by 182.3% during the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company’s stock valued at $15,691,000 after buying an additional 2,155,675 shares during the last quarter. Shay Capital LLC grew its stake in shares of Fulcrum Therapeutics by 4.2% during the 4th quarter. Shay Capital LLC now owns 301,464 shares of the company’s stock worth $1,417,000 after acquiring an additional 12,227 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Fulcrum Therapeutics by 224.0% during the 4th quarter. Millennium Management LLC now owns 76,123 shares of the company’s stock worth $358,000 after acquiring an additional 52,628 shares during the period. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Price Performance

FULC opened at $3.01 on Tuesday. The firm’s fifty day moving average price is $3.53 and its two-hundred day moving average price is $3.72. The company has a market capitalization of $162.48 million, a price-to-earnings ratio of -9.71 and a beta of 2.20. Fulcrum Therapeutics has a 1 year low of $2.78 and a 1 year high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.03). As a group, equities analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current year.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.